BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Twelve patients were enrolled; eight glioblastoma multiforme (GBM), four anaplastic astrocytoma (AA).

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carmustine / therapeutic use. Glioma / drug therapy. Glioma / radiotherapy

[MeSH-minor] Aged. Brain Mapping. Cerebrovascular Circulation / drug effects. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Injections, Intramuscular / methods. Karnofsky Performance Status. Magnetic Resonance Imaging / methods. Male. Middle Aged. Thallium. Tomography Scanners, X-Ray Computed. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuro Oncol. 2000 Jan;2(1):45-59 [11302254.001]

[Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1351-6 [2689399.001]

[Cites] J Neurooncol. 2003 May;62(3):251-8 [12777076.001]

[Cites] Neurosurg Focus. 2003 Feb 15;14(2):e2 [15727423.001]

[Cites] Clin Cancer Res. 2004 Nov 1;10(21):7182-91 [15534091.001]

[Cites] Neuroradiology. 2003 Jun;45(6):373-6 [12719953.001]

[Cites] J Neurosurg. 2005 Feb;102(2):267-75 [15739554.001]

[Cites] Cancer. 1986 Apr 1;57(7):1276-80 [3948112.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] Neoplasia. 2003 Jan-Feb;5(1):9-16 [12659665.001]

[Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]

[Cites] J Cereb Blood Flow Metab. 1991 Sep;11(5):753-61 [1874807.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]

[Cites] Neoplasia. 2003 Jan-Feb;5(1):17-22 [12659666.001]

[Cites] Stroke. 1977 Jan-Feb;8(1):51-7 [13521.001]

[Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]

[Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]

[Cites] CNS Drugs. 2001;15(9):719-43 [11580310.001]

[Cites] J Neurosurg. 2001 Sep;95(3):379-80 [11565856.001]

[Cites] Neuroradiology. 2006 Oct;48(10):703-13 [16937145.001]

[Cites] Ann Neurol. 2005 Jan;57(1):136-9 [15622544.001]

[Cites] Neurosurgery. 1988 Mar;22(3):465-73 [2452376.001]

[Cites] Neuro Oncol. 2001 Oct;3(4):241-5 [11584893.001]

[Cites] Cancer Res. 1988 Aug 15;48(16):4489-92 [3396000.001]

[Cites] Magn Reson Imaging. 2007 Apr;25(3):303-10 [17371718.001]

[Cites] J Neurooncol. 2005 Jul;73(3):225-38 [15980973.001]

[Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):402-8 [16484419.001]

[Cites] J Nucl Med. 1998 May;39(5):786-90 [9591575.001]

[Cites] Clin Cancer Res. 2004 Dec 1;10(23):7852-9 [15585617.001]

[Cites] J Neurooncol. 2001 Aug;54(1):1-8 [11763417.001]

[Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]

[Cites] Mutat Res. 1990 Nov-Dec;233(1-2):117-26 [2233793.001]

[Cites] Acta Oncol. 1995;34(3):335-8 [7779419.001]

[Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):99-104 [7721644.001]

[Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]

[Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]

(PMID = 20063175.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AD84R52XLF / Thallium; U68WG3173Y / Carmustine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: In University of Pittsburgh Cancer Institute (UPCI) protocol 95-033, adult participants with recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) received gross total resection (GTR) of the recurrent tumors, followed by two vaccinations with autologous fibroblasts retrovirally transfected with TFG-IL4-Neo-TK vector admixed with irradiated autologous glioma cells.

[MeSH-major] Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Fibroblasts / metabolism. Glioblastoma / therapy. Interleukin-4 / genetics. Transfection

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol. 2005 Jun 1;174(11):7194-201 [15905564.001]

[Cites] Gene Ther. 2005 May;12(9):733-41 [15772692.001]

[Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]

[Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]

[Cites] Cancer Res. 2006 Apr 15;66(8):4478-87 [16618775.001]

[Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]

[Cites] J Transl Med. 2007;5:10 [17295916.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6451-8 [17616706.001]

[Cites] Hum Gene Ther. 2000 Mar 1;11(4):637-53 [10724042.001]

[Cites] Cancer Gene Ther. 2000 Mar;7(3):486-94 [10766355.001]

[Cites] J Immunol. 2000 Aug 15;165(4):1877-81 [10925267.001]

[Cites] J Exp Med. 2000 Sep 18;192(6):823-33 [10993913.001]

[Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]

[Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]

[Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]

[Cites] Gene Ther. 2001 Aug;8(15):1157-66 [11509946.001]

[Cites] Nat Immunol. 2001 Nov;2(11):1054-60 [11600887.001]

[Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]

[Cites] Oncogene. 2003 May 19;22(20):3188-92 [12789295.001]

[Cites] Blood. 2003 Jul 1;102(1):36-42 [12560234.001]

[Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]

[Cites] J Clin Oncol. 2003 Oct 15;21(20):3826-35 [14551301.001]

[Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):218-27 [15102348.001]

[Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):5934-7 [15342370.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]

[Cites] Hum Gene Ther. 1994 Jan;5(1):41-55 [8155771.001]

[Cites] J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238-48 [7582260.001]

[Cites] Hum Gene Ther. 1996 Mar 1;7(4):479-87 [8800742.001]

[Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]

[Cites] J Invest Dermatol. 1998 May;110(5):762-6 [9579542.001]

[Cites] Forum (Genova). 1998 Oct-Dec;8(4):357-64 [9863030.001]

[Cites] Science. 1999 Feb 19;283(5405):1183-6 [10024247.001]

[Cites] Gene Ther. 1999 Feb;6(2):219-26 [10435106.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]

[Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]

(PMID = 18093335.001).

[ISSN] 1479-5876

[Journal-full-title] Journal of translational medicine

[ISO-abbreviation] J Transl Med

[Language] eng

[Grant] United States / NCATS NIH HHS / TR / UL1 TR000005

[Publication-type] Clinical Trial, Phase I; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Cancer Vaccines; 207137-56-2 / Interleukin-4

[Other-IDs] NLM/ PMC2254376

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We previously found that FoxM1B is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly angiogenic glioblastoma in nude mice.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]

[Cites] Genes Dev. 2008 Feb 15;22(4):449-62 [18258752.001]

[Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]

[Cites] Cancer Res. 2001 May 15;61(10):4143-54 [11358838.001]

[Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]

[Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] Oncogene. 2002 Mar 27;21(13):2058-65 [11960378.001]

[Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]

[Cites] Oncogene. 2002 Dec 5;21(55):8404-13 [12466961.001]

[Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]

[Cites] Semin Cancer Biol. 2004 Apr;14(2):123-30 [15018896.001]

[Cites] Genes Dev. 2004 Apr 1;18(7):830-50 [15082532.001]

[Cites] BMC Cancer. 2003 Sep 17;3:23 [13678425.001]

[Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]

[Cites] Cytokine Growth Factor Rev. 2004 Oct;15(5):297-324 [15450248.001]

[Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]

[Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]

[Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]

[Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]

[Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]

[Cites] Mol Cell Biol. 1995 Oct;15(10):5363-8 [7565686.001]

[Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]

[Cites] Pediatr Neurosurg. 1996;24(1):41-9 [8817614.001]

[Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]

[Cites] Mol Cell Biol. 1997 Mar;17(3):1626-41 [9032290.001]

[Cites] Nucleic Acids Res. 1997 May 1;25(9):1715-9 [9108152.001]

[Cites] J Biol Chem. 1997 Aug 8;272(32):19827-36 [9242644.001]

[Cites] Cancer Res. 1997 Sep 1;57(17):3860-4 [9288800.001]

[Cites] Mol Biol Cell. 1998 Feb;9(2):469-81 [9450968.001]

[Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]

[Cites] Int J Cancer. 1999 Mar 31;81(1):118-24 [10077162.001]

[Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]

[Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]

[Cites] Nat Cell Biol. 2005 Feb;7(2):126-36 [15654331.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2065-9 [15781613.001]

[Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]

[Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]

[Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]

[Cites] J Biol Chem. 2005 Jun 10;280(23):22278-86 [15817462.001]

[Cites] Cancer Res. 2005 Jun 15;65(12):5181-9 [15958562.001]

[Cites] Cancer Res. 2006 Feb 1;66(3):1712-20 [16452231.001]

[Cites] Cancer Res. 2006 Feb 15;66(4):2153-61 [16489016.001]

[Cites] Cancer Res. 2006 Apr 1;66(7):3593-602 [16585184.001]

[Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]

[Cites] Gastroenterology. 2007 Apr;132(4):1420-31 [17408638.001]

[Cites] Cancer Res. 2007 Sep 1;67(17):8293-300 [17804744.001]

[Cites] Oncogene. 2007 Sep 13;26(42):6212-9 [17404569.001]

[Cites] Clin Cancer Res. 2000 Jun;6(6):2562-72 [10873113.001]

(PMID = 18974115.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA116528-03; United States / NCI NIH HHS / CA / CA116528-03; United States / NCI NIH HHS / CA / R01-CA-116528; United States / NCI NIH HHS / CA / R01 CA116528; United States / NCI NIH HHS / CA / R01 CA116528-02; United States / NCI NIH HHS / CA / CA116528-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Vascular Endothelial Growth Factor A

[Other-IDs] NLM/ NIHMS67455; NLM/ PMC2597644

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic oligoastrocytoma in Turcot syndrome.

Turcot syndrome (TS), a rare variant of hereditary non-polyposis colorectal cancer (HNPCC), is characterized by familial clustering of cancer of the large bowel, extracolonic body sites and brain.

We report a 72 year old woman with anaplastic oligoastrocytoma in the setting of TS.

Careful analysis of tumor DNA is required to exclude the chance occurrence of a brain tumor in HNPCC kindreds and increase our understanding of the pathogenesis of the disease.

[MeSH-major] Astrocytoma / complications. Colorectal Neoplasms, Hereditary Nonpolyposis / complications

Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.

Genetic Alliance. consumer health - Oligoastrocytoma.

Genetic Alliance. consumer health - Turcot syndrome.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]

[Cites] J Mol Diagn. 2000 Feb;2(1):20-8 [11272898.001]

[Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):75-81 [10337989.001]

[Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]

[Cites] Genomics. 1994 Dec;24(3):516-26 [7713503.001]

[Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]

[Cites] Nature. 1996 Aug 8;382(6591):499-500 [8700220.001]

[Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]

[Cites] Nature. 1994 Sep 1;371(6492):75-80 [8072530.001]

[Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]

[Cites] Int J Cancer. 1996 Feb 8;65(4):422-5 [8621220.001]

[Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]

[Cites] N Engl J Med. 1996 Mar 14;334(11):736-7 [8594446.001]

[Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]

[Cites] Jpn J Clin Oncol. 2002 Jun;32(6):215-8 [12110639.001]

[Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]

[Cites] Hum Mol Genet. 2000 Jan 22;9(2):283-7 [10607839.001]

[Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]

[Cites] Nervenarzt. 2002 Feb;73(2):177-82 [11975096.001]

[Cites] J Neurosurg. 1999 May;90(5):946-50 [10223463.001]

[Cites] Int J Cancer. 1995 Dec 20;64(6):430-3 [8550246.001]

[Cites] Nat Genet. 1999 Oct;23(2):142-4 [10508506.001]

[Cites] J Med Genet. 1995 Nov;32(11):909-12 [8592341.001]

[Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]

[Cites] Oncogene. 1997 Dec 4;15(23):2877-81 [9419979.001]

(PMID = 19495563.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / Mismatch Repair Endonuclease PMS2; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.

INTRODUCTION: Even low-grade astrocytomas infiltrate the entire brain, a feature that precludes their successful therapy.

So to assess the invasive potential of astrocytoma is very important.

The aim of this study was determine whether there is a significant correlation between the results of (1)H-magnetic resonance spectroscopy ((1)H-MRS) and tumor invasive potential of astrocytoma, which is reflected by expression of matrix metalloproteinase-2 (MMP-2).

According to the World Health Organization classification criteria for central nervous system tumors, there were 16 low-grade astrocytomas (2 pilocytic astrocytomas, 14 grade II astrocytomas) and 25 high-grade astrocytomas (5 anaplastic astrocytomas, 20 glioblastomas).The choline/N-acetylaspartate (Cho/NAA) and choline/creatine (Cho/Cr) ratios were calculated.

Of the 41 astrocytomas, 19 (8 low-grade and 11 high-grade) were analyzed immunohistochemically.

RESULTS: The Cho/NAA and Cho/Cr ratios of high-grade astrocytoma were both significantly greater than those of low-grade astrocytoma (t = -6.222, P = 0.000; t = -6.533, P = 0.000, respectively).

MMP-2 COD values of high-grade astrocytomas were also significantly greater than those of low-grade astrocytomas (t = -5.892, P = 0.000).

[MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Magnetic Resonance Spectroscopy. Matrix Metalloproteinase 2 / metabolism

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. (L)-ASPARTIC ACID .

Hazardous Substances Data Bank. CREATINE .

Hazardous Substances Data Bank. CHOLINE CHLORIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14 [11994741.001]

[Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]

[Cites] Neuroradiology. 2006 May;48(5):312-8 [16552583.001]

[Cites] Radiology. 2006 Mar;238(3):958-69 [16424238.001]

[Cites] Pharmacol Res. 2002 Aug;46(2):155-63 [12220955.001]

[Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]

[Cites] NMR Biomed. 2004 Feb;17(1):10-20 [15011246.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8904-9 [12861074.001]

[Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]

[Cites] Br J Cancer. 2000 Jan;82(1):52-5 [10638966.001]

[Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]

[Cites] Stereotact Funct Neurosurg. 2004;82(2-3):90-7 [15305081.001]

[Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]

[Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]

[Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]

[Cites] Nat Rev Neurosci. 2001 Jul;2(7):502-11 [11433375.001]

[Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]

[Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23 (10 ):1775-8 [12427638.001]

(PMID = 17763847.001).

[ISSN] 0028-3940

[Journal-full-title] Neuroradiology

[ISO-abbreviation] Neuroradiology

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; EC 3.4.24.24 / Matrix Metalloproteinase 2; MU72812GK0 / Creatine; N91BDP6H0X / Choline

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE AND IMPORTANCE: Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade astrocytoma of adolescence.

Results of the histological examination were consistent with a diagnosis of PXA.

The patient was treated with whole-brain radiation of 3600 cGy, with additional intensity-modulated boosts to the enhancing lesions of 1440 cGy.

CONCLUSION: Synchronous multicentric PXA presents unique challenges in that gross total resection would impose significant surgical morbidity; histological homogeneity among the lesions cannot be confirmed; and the well-described potential for anaplastic transformation may be increased with multiple lesions.

The optimal treatment for patients with this rare and challenging diagnosis awaits further study.

[MeSH-major] Astrocytoma. Brain Neoplasms. Neoplasms, Multiple Primary

Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15987556.001).

[ISSN] 1524-4040

[Journal-full-title] Neurosurgery

[ISO-abbreviation] Neurosurgery

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Twenty-two patients had glioblastoma multiforme (GBM), 2 had anaplastic astrocytoma, and 1 had an anaplastic oliogodendroglioma; 24 patients had received one prior chemo therapy regimen before being enrolled in the study.

The most common atrasentan-related toxicities were grade 1 or 2 rhinitis, fatigue, and edema.

One patient developed grade 3 hypoxia and peripheral edema at a dose of 90 mg/day.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]

[Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]

[Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]

[Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]

[Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]

[Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]

[Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]

[Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]

[Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]

[Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]

[Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]

[Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]

[Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]

[Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]

[Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]

[Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]

[Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]

[Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]

[Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]

[Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]

[Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]

[Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]

(PMID = 18477765.001).

[ISSN] 1522-8517

[Journal-full-title] Neuro-oncology

[ISO-abbreviation] Neuro-oncology

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475

[Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan

[Other-IDs] NLM/ PMC2666236

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

WHO grading of human brain tumors extends beyond a strictly histological grading system by providing a basis predictive for the clinical behavior of the respective neoplasm.

For example, patients with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III.

Here we provide evidence that the IDH1 status is more prognostic for overall survival than standard histological criteria that differentiate high-grade astrocytomas.

We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.

Patients with anaplastic astrocytomas carried IDH1 mutations in 60%, and patients with glioblastomas in 7.2%.

IDH1 was the most prominent single prognostic factor (RR 2.7; 95% CI 1.6-4.5) followed by age, diagnosis and MGMT.

The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).

In this combined set of anaplastic astrocytomas and glioblastomas both, IDH1 mutation and IDH1 expression status were of greater prognostic relevance than histological diagnosis according to the current WHO classification system.

We propose to complement the current WHO classification and grading of high-grade astrocytic gliomas by the IDH1 mutation status and to use this combined histological and molecular classification in future clinical trials.

[MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Glioma / classification. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics

[MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / pathology. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21088844.001).

[ISSN] 1432-0533

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Diffuse bone marrow metastasis in cerebellar high-grade astrocytoma. A case report].

[Transliterated title] Metastasis difusa de la medula osea en un astrocitoma cerebeloso de alto grado. Un caso clinico.

INTRODUCTION: Cerebellar high-grade astrocytoma is uncommon.

CASE REPORT: A 46 year-old man with cerebellar anaplastic astrocytoma who developed pancytopenia due to extensive bone marrow metastases.

CONCLUSION: Extraneural metastases of brain gliomas are rare and the spread to the bone marrow confers an extremely poor prognosis for these patients.

[MeSH-major] Astrocytoma / pathology. Bone Marrow Neoplasms / secondary. Cerebellar Neoplasms / pathology

Genetic Alliance. consumer health - Diffuse Astrocytoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19263392.001).

[ISSN] 1576-6578

[Journal-full-title] Revista de neurologia

[ISO-abbreviation] Rev Neurol

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PATIENTS AND METHODS: Eight patients with histologically verified gliomas, comprising 2 cases with glioblastoma multiforme (GBM, grade 4), 5 cases with anaplastic oligodendroglioma (AO, grade 3; high-grade glioma), and 1 case with fibrillary astrocytoma (FA, grade 2; low-grade glioma) were evaluated using the 1H-MRS protocol following conventional MR imaging, diffusion-weighted imaging (DWI), and perfusion-weighted imaging (PWI) preoperatively.

RESULTS: High-grade gliomas tended to demonstrate signal hyperintensity by DWI and higher relative cerebral blood volume (rCBV) by PWI.

The presence of lactate and lipid was predominately detected in patients with high-grade glioma.

[MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17970039.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Protons

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Neurofibromatosis Type 1 (NF1) is a common autosomal dominant neurogenetic disorder characterized by neoplasms involving the nervous system which typically present in children.

A biopsy was performed and pathological examination revealed an anaplastic pleomorphic xanthoastrocytoma (PXA).

Although she did not meet the accepted clinical criteria for NF1, given that she has a sibling with NF1 and a malignancy observed in this disorder, we hypothesize that she also has NF1.

Our genetic analysis indicated a shared haplotype in these siblings who developed brain tumors but not in an unaffected sister suggesting that both carry the NF1 disease-producing allele.

CONCLUSION: NF1 should be a diagnostic consideration when siblings develop intracranial brain tumors even when they develop in adults.

[MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Neurofibromatosis 1 / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16725158.001).

[ISSN] 0022-510X

[Journal-full-title] Journal of the neurological sciences

[ISO-abbreviation] J. Neurol. Sci.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability.

Glioblastoma multiforme (GBM) and other high-grade brain tumours are typically characterized by complex chromosome abnormalities and extensive intratumour cytogenetic heterogeneity.

In this study, we analysed the pattern of chromosome segregation at mitosis in 20 brain tumours.

Anaphase bridging was also found in two medulloblastomas (7-15%), one anaplastic astrocytoma (17%) and one oligodendroglioma (6%).

In contrast, cell division abnormalities were not found in low-grade brain tumours with less complex karyotypes, including two pilocytic astrocytomas and two ependymomas.

Telomere-dependent abnormal segregation of chromosomes at mitosis is thus a common phenomenon in high-grade brain tumours and may be one important factor behind cytogenetic intratumour diversity in GBM.

[MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Spindle Apparatus / pathology. Telomere / pathology

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17617873.001).

[ISSN] 0305-1846

[Journal-full-title] Neuropathology and applied neurobiology

[ISO-abbreviation] Neuropathol. Appl. Neurobiol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] EC 2.7.7.49 / Telomerase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Targeting the epidermal growth factor receptor in high-grade astrocytomas.

OPINION STATEMENT: High-grade astrocytomas, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), are the most common and aggressive primary malignant brain tumors in adults.

[MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Lett. 2003 Dec 8;202(1):43-51 [14643025.001]

[Cites] Clin Cancer Res. 2006 Sep 1;12(17):5064-73 [16951222.001]

[Cites] Neurology. 2005 Apr 26;64(8):1444-5 [15851741.001]

[Cites] Neurosurgery. 2002 Oct;51(4):1005-13; discussion 1013-4 [12234411.001]

[Cites] Oncogene. 2000 Dec 27;19(56):6550-65 [11426640.001]

[Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):873-82 [17544000.001]

[Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]

[Cites] J Cell Biochem. 2007 Nov 1;102(4):869-77 [17868090.001]

[Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8757-64 [16314636.001]

[Cites] Int J Cancer. 2002 Oct 20;101(6):567-75 [12237899.001]

[Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]

[Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]

[Cites] Clin Cancer Res. 1996 Dec;2(12):1931-5 [9816151.001]

[Cites] Clin Cancer Res. 2002 Nov;8(11):3496-502 [12429640.001]

[Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]

[Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]

[Cites] Cancer Biol Ther. 2006 Apr;5(4):375-9 [16575203.001]

[Cites] BMC Cancer. 2006 May 18;6:133 [16709245.001]

[Cites] Clin Cancer Res. 2003 Sep 15;9(11):4247-54 [14519652.001]

[Cites] J Clin Invest. 2007 Feb;117(2):346-52 [17256054.001]

[Cites] Mol Cancer Ther. 2007 Mar;6(3):1167-74 [17363510.001]

[Cites] Neurosurgery. 2005;56(1):155-62; discussion 162 [15617598.001]

[Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]

[Cites] Clin Cancer Res. 2001 Aug;7(8):2387-95 [11489817.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]

[Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]

[Cites] Cancer Res. 2003 Dec 15;63(24):8930-8 [14695210.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6 [17360479.001]

[Cites] Cancer Res. 2007 Sep 1;67(17 ):7960-5 [17804702.001]

[Cites] Crit Rev Oncol Hematol. 2006 Dec;60(3):181-93 [16875833.001]

[Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]

[Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]

(PMID = 18247132.001).

[ISSN] 1534-6277

[Journal-full-title] Current treatment options in oncology

[ISO-abbreviation] Curr Treat Options Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

[Number-of-references] 54

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does vasculogenic mimicry exist in astrocytoma?

It is unknown whether a similar VM phenomenon exists in astrocytoma.

The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.

PAS-positive pattern of VM was found in two grade IV astrocytomas.

Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.

It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.

The present results suggest that VM phenomenon exists in some malignant astrocytoma.

[MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15923371.001).

[ISSN] 0022-1554

[Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

[ISO-abbreviation] J. Histochem. Cytochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas.

[MeSH-major] Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Glioma / enzymology. Glioma / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics

[MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / enzymology. Astrocytoma / genetics. Carcinoma / drug therapy. Carcinoma / enzymology. Carcinoma / genetics. DNA Mutational Analysis. Drug Resistance, Neoplasm / genetics. Genetic Testing. Glioblastoma / drug therapy. Glioblastoma / enzymology. Glioblastoma / genetics. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / enzymology. Oligodendroglioma / genetics. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Structure, Tertiary / genetics. Quinazolines / pharmacology. Quinazolines / therapeutic use

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. OMIM: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15851741.001).

[ISSN] 1526-632X

[Journal-full-title] Neurology

[ISO-abbreviation] Neurology

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Natural history of supratentorial low-grade astrocytoma: case report].

Low-grade astrocytomas comprise a group of primary brain neoplasms with relatively low anaplastic potential, although through time they tend to behave more aggressively.

This report presents a natural history of a patient with low grade astrocytoma.

Initial computerized tomography and magnetic resonance of brain revealed oval, 4 cm in diameter, lesion in the left parietal region that was considered as low-grade glioma.

The described patient with low-grade astrocytoma lived without any oncological treatment eight years and four months from the time when diagnosis was made until intracranial herniation.

The natural history of disease in presented patient indicated that rational therapeutic strategy, for low-grade astrocytoma with epilepsy only, would be deferral of surgery until the time of manifestation of neurological or radiological deterioration.

[MeSH-major] Astrocytoma. Brain Neoplasms. Parietal Lobe

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17304770.001).

[ISSN] 0370-8179

[Journal-full-title] Srpski arhiv za celokupno lekarstvo

[ISO-abbreviation] Srp Arh Celok Lek

[Language] srp

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Serbia and Montenegro

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.

A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma.

Histological examination of surgical specimens revealed neurocysticercosis between the normal brain tissue and glioblastoma.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Neurocysticercosis / pathology

Genetic Alliance. consumer health - Turcot syndrome.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17138070.001).

[ISSN] 0967-5868

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Scotland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.

METHODS AND MATERIALS: Fifty-eight consecutive high-grade gliomas were treated between January 2001 and December 2003 with dynamic multileaf collimator IMRT, planned with the inverse approach.

Glioblastoma accounted for 70% of the cases, and anaplastic oligodendroglioma histology (pure or mixed) was seen in 15% of the cases.

The median progression-free survival time for anaplastic astrocytoma and glioblastoma histology was 5.6 and 2.5 months, respectively.

The overall survival time for anaplastic glioma and glioblastoma was 36 and 9 months, respectively.

No Grade IV/V late neurologic toxicities were noted.

Intensity-modulated radiotherapy delivered with a limited number of beams did not result in an increased dose to the normal brain.

CONCLUSIONS: It is unlikely that IMRT will improve local control in high-grade gliomas without further dose escalation compared with conventional radiotherapy.

[MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy, Intensity-Modulated

[MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / radiation effects. Disease Progression. Female. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Oligodendroglioma / radiotherapy. Radiotherapy Dosage. Retrospective Studies

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16458777.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

YKL-40 is a secreted chitinase-like molecule whose expression is associated with glioma grade.

A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-grade adult glio-mas, including 28 anaplastic oligodendrogliomas (AOs) and 51 GBMs.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]

[Cites] Oncogene. 2009 Dec 17;28(50):4456-68 [19767768.001]

[Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]

[Cites] Biochem J. 2002 Jul 1;365(Pt 1):119-26 [12071845.001]

[Cites] Cancer. 2002 Jul 15;95(2):267-74 [12124825.001]

[Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]

[Cites] Int J Cancer. 2002 Oct 10;101(5):454-60 [12216074.001]

[Cites] J Neurosurg. 2002 Dec;97(6):1397-401 [12507139.001]

[Cites] Clin Cancer Res. 2003 Oct 1;9(12):4423-34 [14555515.001]

[Cites] Biochem J. 2004 Jun 15;380(Pt 3):651-9 [15015934.001]

[Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]

[Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]

[Cites] Cancer Sci. 2005 Mar;96(3):183-90 [15771622.001]

[Cites] Clin Cancer Res. 2005 Mar 15;11(6):2258-64 [15788675.001]

[Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]

[Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]

[Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8644-52 [16361549.001]

[Cites] Neurosurg Focus. 2005 Nov;19(5):E2 [16398466.001]

[Cites] Cancer. 2006 Mar 1;106(5):1130-9 [16456816.001]

[Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]

[Cites] J Biol Chem. 2006 Oct 6;281(40):29583-96 [16882657.001]

[Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56 [17146289.001]

[Cites] Gynecol Oncol. 2007 Feb;104(2):435-42 [17023034.001]

[Cites] World J Surg Oncol. 2007;5:17 [17286869.001]

[Cites] Clin Cancer Res. 2007 Mar 1;13(5):1429-37 [17332285.001]

[Cites] J Clin Oncol. 2007 Jun 1;25(16):2288-94 [17538175.001]

[Cites] Clin Cancer Res. 2007 Jun 1;13(11):3244-9 [17545529.001]

[Cites] Int J Cancer. 2008 Feb 15;122(4):857-63 [17957792.001]

[Cites] Urol Oncol. 2008 Jan-Feb;26(1):47-52 [18190830.001]

[Cites] Eur J Haematol. 2008 Apr;80(4):310-7 [18182077.001]

[Cites] Int J Cancer. 2008 May 15;122(10):2187-98 [18092325.001]

[Cites] Am J Pathol. 2008 Jul;173(1):130-43 [18556781.001]

[Cites] Adv Ther. 2008 Aug;25(8):801-9 [18670741.001]

[Cites] FEBS Lett. 2008 Sep 22;582(21-22):3193-200 [18708058.001]

[Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]

[Cites] Ann Oncol. 2009 Jan;20(1):71-7 [18723551.001]

[Cites] J Clin Oncol. 2009 Feb 1;27(4):572-8 [19075264.001]

[Cites] BMC Cancer. 2009;9:8 [19134206.001]

[Cites] Brain Pathol. 2009 Jul;19(3):439-48 [18652591.001]

[Cites] Biochem Biophys Res Commun. 2009 Oct 23;388(3):511-6 [19666003.001]

[Cites] Hum Pathol. 2009 Dec;40(12):1790-7 [19765801.001]

[Cites] Clin Cancer Res. 2002 Jan;8(1):196-201 [11801559.001]

(PMID = 20224722.001).

[ISSN] 1936-2625

[Journal-full-title] International journal of clinical and experimental pathology

[ISO-abbreviation] Int J Clin Exp Pathol

[Language] ENG

[Grant] United States / NIMH NIH HHS / MH / K24 MH001717; United States / PHS HHS / / K24 M401717

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

[Other-IDs] NLM/ PMC2836500

[Keywords] NOTNLM ; 10q / 1p19q / EGFR / YKL-40 / glioblastoma / oligodendroglioma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.

Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.

We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.

Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.

Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.

[MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis

Genetic Alliance. consumer health - Diffuse Astrocytoma.

Genetic Alliance. consumer health - Pilocytic astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19543740.001).

[ISSN] 1432-0533

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42 / isocitrate dehydrogenase (NADP+); EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Histological, immunohistochemical and electron microscopic findings were consistent with high-grade ependymoma.

As a result the diagnosis of GCE was established.

This type of neoplasm necessitates, at least in theory, differentiation with anaplastic oligodendroglioma, clear cell ependymoma, pleomorphic xanthoastrocytoma, giant cell glioblastoma, and subependymal giant cell astrocytoma.

[MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Lateral Ventricles

Genetic Alliance. consumer health - Ependymoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18006220.001).

[ISSN] 0303-8467

[Journal-full-title] Clinical neurology and neurosurgery

[ISO-abbreviation] Clin Neurol Neurosurg

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma].

BACKGROUND: Anaplastic astrocytomas in neonates are extremely rare.

An ultrasound scan of the brain showed an intracerebral bleeding.

No tumour was found, but an anaplastic astrocytoma (WHO Grade III) was diagnosed histologically.

Serial ultrasound investigations of the brain showed a normal midline and a redevelopment of the left-sided ventricle.

CONCLUSION: Congenital anaplastic astrocytomas have a variable outcome, with different survival rates as compared to adults.

[MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Cerebral Hemorrhage / congenital

[MeSH-minor] Diagnosis, Differential. Echoencephalography. Fatal Outcome. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Occipital Lobe / pathology. Temporal Lobe / pathology. Tomography, X-Ray Computed. Trephining

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18956278.001).

[ISSN] 0948-2393

[Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie

[ISO-abbreviation] Z Geburtshilfe Neonatol

[Language] ger

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to grade 3.

Based on the differences in patient selection with respect to the definition of AO (2 versus 3 high risk anaplastic features) and sequence of treatment (RT and chemotherapy), the results from the two RCTs were not able to be considered for meta-analysis.

[MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[UpdateIn] Cochrane Database Syst Rev. 2014;5:CD007104 [24833028.001]

(PMID = 18425979.001).

[ISSN] 1469-493X

[Journal-full-title] The Cochrane database of systematic reviews

[ISO-abbreviation] Cochrane Database Syst Rev

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 11

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.

The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.

Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.

No grade 3 or 4 toxicities were noted in this study.

[MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carboplatin / therapeutic use. Decanoic Acids / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Polyesters / therapeutic use

Genetic Alliance. consumer health - Glioblastoma.

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. CARBOPLATIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Neurol. 2000 Dec;13(6):619-25 [11148660.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]

[Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]

[Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]

[Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]

[Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]

[Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]

[Cites] Neuro Oncol. 2001 Oct;3(4):246-50 [11584894.001]

[Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]

[Cites] Cancer Chemother Pharmacol. 1997;39(4):376-9 [9025780.001]

[Cites] J Control Release. 1999 Aug 27;61(1-2):21-41 [10469900.001]

[Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]

(PMID = 15937647.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue.

ApoD expression was investigated by real-time quantitative RT-PCR using RNA extracted from 68 formalin-fixed, paraffin-embedded brain specimens.

Sixteen poorly infiltrating WHO grade I glial neoplasms (i.e., pilocytic astrocytomas and gangliogliomas) showed an average 20-fold higher apoD expression level compared with the 20 diffusely infiltrating glial neoplasms (i.e., glioblastoma, anaplastic astrocytoma, oligodendrogliomas; p=0.00004).

Analyzed as individual tumor groups, poorly infiltrating grade I pilocytic astrocytomas and gangliogliomas differed significantly from each tumor type within the diffusely infiltrating higher-grade category (p<0.05 for each comparison) but not from each other (p>0.05).

Ependymomas, non-infiltrating grade II neoplasms, expressed levels of apoD similar to or lower than levels expressed by the diffusely infiltrating gliomas.

In addition, apoD expression was 5-fold higher in the slowly proliferating grade I glial neoplasms compared with non-proliferating normal brain tissue (p=0.01), suggesting that apoD expression is not simply an inverse measure of proliferation.

ApoD expression measured by quantitative RT-PCR may be useful in the differential diagnosis of primary brain tumors, particularly pilocytic astrocytomas and gangliogliomas.

[MeSH-major] Apolipoproteins / biosynthesis. Brain Neoplasms / metabolism. Glioma / metabolism

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FORMALDEHYDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16055749.001).

[ISSN] 0022-1554

[Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

[ISO-abbreviation] J. Histochem. Cytochem.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Apolipoproteins; 0 / Apolipoproteins D; 0 / Fixatives; 0 / Ki-67 Antigen; 1HG84L3525 / Formaldehyde; 8002-74-2 / Paraffin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Although the presence of abundant RFs within brain tumors is most closely associated with a low-grade astrocytoma, particularly pilocytic astrocytoma (PA), a few RFs are recognized to occur, although rarely, in glioblastoma (GBM).

Histologic sections showed diffusely infiltrating astrocytoma with prominent RFs diffusely distributed throughout the tumor, brisk mitotic activity, vascular proliferation, and small areas of necrosis, as seen in a GBM.

DISCUSSION: This is a case of RF-rich GBM (primary or de novo type).

The differential diagnosis includes PA and anaplastic PA.

For the histological diagnosis, infiltrating astrocytoma with abundant RFs should be carefully examined in light of clinical information (e.g., patient age, evolution of the symptoms) and neuroimaging studies.

[MeSH-major] Astrocytes / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology

Genetic Alliance. consumer health - Glioblastoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19537132.001).

[ISSN] 0722-5091

[Journal-full-title] Clinical neuropathology

[ISO-abbreviation] Clin. Neuropathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The aim of this study was to estimate the EGFR serum concentration for potential use as a biological marker of brain cancer to predict prognosis and follow-up after treatment.

METHODS AND STUDY DESIGN: Serum samples obtained from 50 healthy individuals and 65 brain cancer patients (35 glioblastoma multiforme and 30 anaplastic astrocytomas) were collected before and after treatment and assayed for EGFR extracellular domain serum concentrations by a sandwich ELISA.

RESULTS: EGFR was elevated in 47 of 65 brain cancer patients, with mean serum values of 84 +/- 18 ng/ml, compared with that of healthy controls (43.6 +/- 11 ng/ml, P = 0.001).

There was a significant difference in the mean serum levels of EGFR between glioblastoma multiforme patients (96.2 +/- 12 ng/ml) and anaplastic astrocytoma patients (71.6 +/- 18 ng/ml, P = 0.04).

Sixty brain cancer patients underwent surgery; EGFR serum levels did not show significant differences from those observed before surgery.

For all patients, median overall survival was 13 months (anaplastic astrocytoma, 18 months; glioblastoma multiforme, 12.5 months).

In 47 patients with high EGFR serum levels, overall survival was reduced (P = 0.01), with a median survival time corresponding to 11.5 months (anaplastic astrocytoma, 14.5 months; glioblastoma multiforme, 10.5 months).

[MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / blood. Glioma / blood. Neoplasm Proteins / blood. Receptor, Epidermal Growth Factor / blood

[MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / blood. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Glioblastoma / blood. Glioblastoma / drug therapy. Glioblastoma / mortality. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Protein Structure, Tertiary. Radiotherapy, Adjuvant. Signal Transduction. Survival Analysis. Treatment Outcome

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. DACARBAZINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17679463.001).

[ISSN] 0300-8916

[Journal-full-title] Tumori

[ISO-abbreviation] Tumori

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 7GR28W0FJI / Dacarbazine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; YF1K15M17Y / temozolomide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.

The aim of this study was to investigate EGFR gene amplification and expression of c-erbB1-4 receptor proteins in human anaplastic astrocytomas.

The synchronous overexpression of c-erbB1-4 proteins in anaplastic astrocytomas supports their role in the pathogenesis of these tumors.

[MeSH-major] Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Receptor, ErbB-2 / analysis. Supratentorial Neoplasms / chemistry

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Pharmacol. 2008 Feb;73(2):338-48 [17975007.001]

[Cites] J Neurooncol. 2007 Dec;85(3):281-7 [17571214.001]

[Cites] J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23 [18454306.001]

[Cites] J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):259-68 [18454307.001]

[Cites] Curr Treat Options Oncol. 2008 Feb;9(1):23-31 [18247132.001]

[Cites] Exp Cell Res. 2008 Oct 1;314(16):2907-18 [18687326.001]

[Cites] Minim Invasive Neurosurg. 2009 Feb;52(1):17-24 [19247900.001]

[Cites] Appl Immunohistochem Mol Morphol. 2009 May;17(3):220-6 [19391220.001]

[Cites] J Natl Cancer Inst. 2009 May 20;101(10):736-50 [19436038.001]

[Cites] Brain Pathol. 2009 Oct;19(4):713-23 [19744042.001]

[Cites] Cancer. 2002 Mar 1;94(5):1593-611 [11920518.001]

[Cites] Acta Neurochir (Wien). 2000;142(2):113-37; discussion 137-8 [10795886.001]

[Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]

[Cites] Endocr Relat Cancer. 2001 Jun;8(2):83-96 [11397666.001]

[Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]

[Cites] Cell. 2002 Sep 20;110(6):669-72 [12297041.001]

[Cites] Front Biosci. 2003 Jan 1;8:e1-13 [12456322.001]

[Cites] Brain Pathol. 2003 Jan;13(1):52-61 [12580545.001]

[Cites] Am J Clin Oncol. 2003 Aug;26(4):332-5 [12902879.001]

[Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]

[Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]

[Cites] Diagn Mol Pathol. 2004 Mar;13(1):1-8 [15163002.001]

[Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]

[Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]

[Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]

[Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]

[Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(2):147-55 [2563600.001]

[Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]

[Cites] J Biol Chem. 1991 Jan 25;266(3):1716-20 [1671042.001]

[Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]

[Cites] Cancer Immunol Immunother. 1991;33(1):61-4 [2021959.001]

[Cites] J Neuropathol Exp Neurol. 1992 Jan;51(1):84-90 [1311022.001]

[Cites] J Neurosurg. 1992 Aug;77(2):295-301 [1320666.001]

[Cites] Acta Neurochir (Wien). 1992;117(3-4):182-6 [1414519.001]

[Cites] Eur J Cancer. 1993;29A(11):1604-6 [8105841.001]

[Cites] Int J Cancer. 1994 Jan 2;56(1):72-7 [8262681.001]

[Cites] Hum Pathol. 1994 Aug;25(8):772-80 [7914508.001]

[Cites] J Neurooncol. 1994;22(3):201-7 [7760096.001]

[Cites] Clin Neuropathol. 1995 May-Jun;14(3):169-74 [7671460.001]

[Cites] Neurosurgery. 1995 Aug;37(2):179-93; discussion 193-4 [7477768.001]

[Cites] Br J Cancer. 1996 Mar;73(5):620-3 [8605096.001]

[Cites] Am J Pathol. 1996 Apr;148(4):1047-53 [8644846.001]

[Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]

[Cites] Cancer Res. 1997 Aug 1;57(15):3272-80 [9242460.001]

[Cites] J Neurooncol. 1997 Dec;35(3):335-46 [9440030.001]

[Cites] Clin Cancer Res. 1998 Jan;4(1):215-22 [9516974.001]

[Cites] J Pathol. 1998 Jul;185(3):236-45 [9771476.001]

[Cites] Brain Pathol. 1998 Oct;8(4):655-67 [9804374.001]

[Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]

[Cites] J Neuropathol Exp Neurol. 1998 Dec;57(12):1138-45 [9862636.001]

[Cites] Cancer Invest. 2004;22(4):537-44 [15565811.001]

[Cites] JAMA. 2005 Feb 2;293(5):557-64 [15687310.001]

[Cites] J Exp Clin Cancer Res. 2005 Mar;24(1):89-92 [15943037.001]

[Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S17-27 [16113093.001]

[Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):91-6 [16540738.001]

[Cites] Cancer Treat Rev. 2006 Apr;32(2):74-89 [16488082.001]

[Cites] Neuropathol Appl Neurobiol. 2006 Aug;32(4):441-50 [16866989.001]

[Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):56-8 [17536308.001]

[Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]

[Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):353-9 [17987795.001]

[Cites] Mol Pharmacol. 2008 Feb;73(2):271-3 [17981994.001]

(PMID = 20331873.001).

[ISSN] 1746-1596

[Journal-full-title] Diagnostic pathology

[ISO-abbreviation] Diagn Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-4

[Other-IDs] NLM/ PMC2859381

[General-notes] NLM/ Original DateCompleted: 20100609

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anaplastic astrocytoma in adults.

Anaplastic astrocytoma is an uncommon disease in the adult population.

Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.

In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for anaplastic astrocytoma .

Hazardous Substances Data Bank. DACARBAZINE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17478095.001).

[ISSN] 1040-8428

[Journal-full-title] Critical reviews in oncology/hematology

[ISO-abbreviation] Crit. Rev. Oncol. Hematol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Review

[Publication-country] Ireland

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

[Number-of-references] 69

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.

BACKGROUND: Anaplastic oligodendroglioma (OD) tumors, especially those with the combined loss of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), are sensitive to chemotherapy.

Only limited data are available on the role of chemotherapy in low-grade OD.

The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD.

A Phase III trial should be initiated to compare radiotherapy with chemotherapy.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. PROCARBAZINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2005 American Cancer Society.

(PMID = 15637687.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.

METHODS: Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11).

The two cohorts were compared for age, histology, prior therapies, extent of surgical resection at progression, and time from initial diagnosis to progression.

Of 56 children with recurrent malignant astrocytoma who received conventional chemotherapy following initial progression, no patient survives.

MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CARBOPLATIN .

Hazardous Substances Data Bank. THIO-TEPA .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3569-74 [10629654.001]

[Cites] J Neurooncol. 2006 Mar;77(1):89-94 [16292488.001]

[Cites] Clin Cancer Res. 2001 Jan;7(1):32-7 [11205914.001]

[Cites] Acta Neurochir (Wien). 2002 Dec;144(12):1265-70; discussion 1270 [12478337.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

[Cites] J Neurosurg. 1981 Apr;54(4):455-60 [6259300.001]

[Cites] J Clin Oncol. 1984 May;2(5):432-7 [6726296.001]

[Cites] J Clin Oncol. 1986 May;4(5):639-45 [3009725.001]

[Cites] J Clin Oncol. 1987 May;5(5):783-9 [3553437.001]

[Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]

[Cites] Br J Cancer. 1988 Dec;58(6):779-82 [2852028.001]

[Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]

[Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]

[Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]

[Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]

[Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]

[Cites] J Neurooncol. 1990 Dec;9(3):239-48 [1964962.001]

[Cites] J Neurooncol. 1991 Apr;10(2):139-44 [1654401.001]

[Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]

[Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]

[Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]

[Cites] J Neurooncol. 1994;19(1):69-74 [7815106.001]

[Cites] Bone Marrow Transplant. 1996 Mar;17(3):389-94 [8704692.001]

[Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]

[Cites] Cancer. 1998 Aug 15;83(4):813-6 [9708950.001]

[Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]

[Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]

(PMID = 18802947.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U10 CA013539; United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / CA013539-30; United States / NCI NIH HHS / CA / U10 CA013539-30; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA021765-259003; United States / NCI NIH HHS / CA / P30 CA021765-259003; None / None / / U10 CA098543-06; United States / NCI NIH HHS / CA / CA 21765

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Myeloablative Agonists; 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine

[Other-IDs] NLM/ NIHMS65899; NLM/ PMC2844080

[Investigator] Bleyer A; Khayat A; Sather H; Krailo M; Buckley J; Stram D; Sposto R; Hutchinson R; Matthay K; Gaynon P; Geyer JR; Shurin S; Reaman G; Ortega J; Ruymann F; Weiner M; Blatt J; Lukens J; Wolff L; Neglia J; Lange B; Steinherz P; Breitfeld P; O'Brien R; Cohen H; Fryer C; Wells R; Finklestein J; Feig S; Tannous R; Odom L; Gilchrist G; Barnard D; Wiley J; Ettinger L; Hetherington M; Coccia P; Norris D; Nachman J; Raney B; Baker D; Sanders J; Rausen A; Cairo M

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.

BACKGROUND: Anaplastic oligoastrocytomas (AOA) are relatively uncommon high-grade gliomas.

METHODS: Between 1980 and 1999, Mayo Clinic and the NCCTG conducted 10 trials of radiation therapy and chemotherapy in adults with newly-diagnosed high-grade gliomas.

We grouped patients by cell type and grade, compared survival distributions by the log-rank statistic, and performed multiple variable analyses.

RESULTS: Of 1368 patients, 68 (5%) had AOA, including 21 Grade 3 (OA3) and 47 grade 4 (OA4), 153 (11%) had anaplastic astrocytoma (AA), and 1147 (84%) had glioblastoma multiforme (GBM).

CONCLUSIONS: Patients with anaplastic oligoastrocytoma have distinct outcomes based upon grade (OA3 vs. OA4) and in comparison with pure astrocytoma (AA or GBM).

Future trials which include more than one histologic entity need to report results by cell type and grade and account for the varying prognoses in interpreting treatment outcomes.

[MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology

Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.

Genetic Alliance. consumer health - Oligoastrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]

[Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]

[Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]

[Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]

[Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]

[Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]

[Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]

[Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]

[Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]

[Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]

[Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]

[Cites] Neurosurgery. 1994 Apr;34(4):577-82; discussion 582 [8008153.001]

[Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]

[Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]

[Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]

[Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

(PMID = 17431544.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].

According to the current WHO classification anaplastic gliomas comprise pure astrocytomas and oligodendrogliomas and mixed tumors.

This review summarizes findings, discusses problems and defines new questions from the phase III trials on anaplastic gliomas.

Therefore, marker profiles should be included into the next WHO brain tumor classification.

The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy.

Inclusion in this trial is already based on the WHO grade and the 1p/19q status and not on the histopathological subtype.

Furthermore, anaplastic gliomas are an important group of brain tumors for developing future molecular targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at improved efficacy and avoiding long-term side-effects.

[MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology

[MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Chromosome Deletion. Clinical Trials as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Cranial Irradiation. DNA Modification Methylases / genetics. DNA Mutational Analysis. DNA Repair Enzymes / genetics. Disease-Free Survival. Humans. Isocitrate Dehydrogenase / genetics. Promoter Regions, Genetic / genetics. Survival Rate. Tumor Suppressor Proteins / genetics

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]

[Cites] J Neurol. 2009 May;256(5):734-41 [19240962.001]

[Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]

[Cites] Cancer Res. 2009 May 15;69(10 ):4502-9 [19366800.001]

[Cites] Eur J Cancer. 2008 Jun;44(9):1210-6 [18248979.001]

[Cites] J Neurooncol. 2009 May;92(3):401-15 [19357966.001]

[Cites] J Clin Oncol. 2010 Apr 20;28(12 ):2051-7 [20308655.001]

[Cites] Nat Rev Neurol. 2010 Jan;6(1):39-51 [19997073.001]

[Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]

[Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]

[Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]

[Cites] Neuro Oncol. 2008 Dec;10 (6):1019-24 [18676355.001]

[Cites] J Clin Oncol. 2009 Dec 10;27(35):5881-6 [19901104.001]

[Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]

[Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]

[Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]

[Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]

[Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]

[Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]

[Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]

[Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]

[Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]

[Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] J Neurosurg. 2008 Feb;108(2):330-5 [18240930.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]

[Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]

[Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]

(PMID = 20635074.001).

[ISSN] 1433-0407

[Journal-full-title] Der Nervenarzt

[ISO-abbreviation] Nervenarzt

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The differential diagnosis between cerebral glioma and infective lesions can be very difficult to distinguish by MRI only.

Brain biopsy revealed anaplastic astrocytoma (WHO III).

CONCLUSION: This case report shows that cerebral glioma can mimick infective brain disease and that MR-spectroscopy is an important non-invasive tool in this differential diagnosis.

[MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis. Cerebellar Neoplasms / diagnosis. Encephalitis / diagnosis. Magnetic Resonance Spectroscopy. Pons

[MeSH-minor] Aspartic Acid / analogs & derivatives. Aspartic Acid / analysis. Child. Choline / analysis. Creatine / analysis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Encephalitis.

Hazardous Substances Data Bank. (L)-ASPARTIC ACID .

Hazardous Substances Data Bank. CREATINE .

Hazardous Substances Data Bank. CHOLINE CHLORIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16865652.001).

[ISSN] 0300-8630

[Journal-full-title] Klinische Pädiatrie

[ISO-abbreviation] Klin Padiatr

[Language] ger

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This study was a preliminary trial of individualized chemotherapy based on MGMT methylation status in a total of 20 patients with newly diagnosed malignant astrocytomas (9 anaplastic astrocytomas and 11 glioblastomas multiforme).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / genetics. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. DNA Methylation. O(6)-Methylguanine-DNA Methyltransferase / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16936459.001).

[ISSN] 0470-8105

[Journal-full-title] Neurologia medico-chirurgica

[ISO-abbreviation] Neurol. Med. Chir. (Tokyo)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Alkylating Agents; 0 / Nitrosourea Compounds; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is it appropriate to redefine the indication for stereotactic brain biopsy in the MRI Era? Correlation with final histological diagnosis in supratentorial gliomas.

BACKGROUND: The aim of this study was to evaluate the advisability of modifying the indications for stereotactic brain biopsy (SBB) in high- and low-grade supratentorial glial tumors in correlation with the diagnostic accuracy of magnetic resonance imaging (MRI).

On the basis of the MRI findings the patients were divided into two groups: high-grade (n=107) and low-grade (n=67) gliomas.

Only one preoperative diagnosis was allowed.

RESULTS: A final histological diagnosis was achieved in 95% of the 174 cases.

In the group of high-grade gliomas (HGG) there was diagnostic coincidence in 87% of cases, reaching 100% in lesions of the corpus callosum.

In 11 cases (10%) the histological analysis changed the presumptive diagnosis and the consequent management.

In the group of low-grade gliomas (LGG) there was diagnostic coincidence in 63% (42 cases), whereas there was discordance in 30%: 10 cases were upgraded to anaplastic astrocytoma, and in 10 cases no tumors were observed at all.

CONCLUSIONS: In the future, the histological diagnosis of glial tumors will include molecular genetic definition, thus making it crucial for management using the new therapeutic options.

Today, the indications for biopsy in lesions mimicking high-grade gliomas are mainly linked to the site of the tumor, coexisting differential diagnoses or more than one treatment option.

On the contrary, in lesions where MRI findings indicate low-grade gliomas, grading is crucial also in order to avoid treatment inappropriate in non-neoplastic lesions.

[MeSH-major] Astrocytoma / pathology. Brain / pathology. Glioma / pathology. Magnetic Resonance Imaging / standards. Neoplasm Recurrence, Local / pathology. Stereotaxic Techniques / standards. Supratentorial Neoplasms / pathology

[MeSH-minor] Adolescent. Adult. Aged. Child. Corpus Callosum / pathology. Corpus Callosum / radiography. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Humans. Male. Middle Aged. Necrosis. Observer Variation. Predictive Value of Tests. Radiation Injuries / pathology. Radiation Injuries / radiography. Retrospective Studies. Tomography, X-Ray Computed

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18401825.001).

[ISSN] 0946-7211

[Journal-full-title] Minimally invasive neurosurgery : MIN

[ISO-abbreviation] Minim Invasive Neurosurg

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.

Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).

Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.

We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.

We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA.

More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.

Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.

[MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

MedlinePlus Health Information. consumer health - Brain Tumors.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20711171.001).

[ISSN] 1530-0285

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas.

We examined two anaplastic astrocytomas showing minimal contrast-enhancement and therefore little damage of the blood brain barrier to minimise the presence of blood borne macrophages within tumour tissue.

The expression profile of four anaplastic astrocytomas was also exploited and results were compared to the profile of eleven samples of normal temporal lobe and nine cases of PD.

[MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Microglia / metabolism. Microglia / pathology. Receptors, GABA-A / biosynthesis

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

ORBi (University of Liege). Free full Text at ORBi .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] BMC Bioinformatics. 2006 Dec 01;7:526 [17140431.001]

[Cites] Glia. 2002 Nov;40(2):206-17 [12379908.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] Dev Neurosci. 2004 Jan-Feb;26(1):30-7 [15509896.001]

[Cites] Ann Neurol. 1988 Dec;24(6):708-12 [2849920.001]

[Cites] Acta Neuropathol. 1996 Sep;92(3):288-93 [8870831.001]

[Cites] J Neurochem. 2000 Apr;74(4):1694-704 [10737628.001]

[Cites] Neurobiol Dis. 2003 Dec;14 (3):417-24 [14678758.001]

[Cites] J Neurooncol. 1998 May;38(1):19-26 [9540054.001]

[Cites] Lab Invest. 1994 Jan;70(1):23-8 [8302015.001]

[Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):293-301 [9775395.001]

[Cites] Trends Pharmacol Sci. 2006 Aug;27(8):402-9 [16822554.001]

[Cites] Acta Neurochir (Wien). 1992;119(1-4):146-52 [1336303.001]

[Cites] Brain. 2004 Jun;127(Pt 6):1379-92 [15069023.001]

[Cites] Cancer Res. 1988 Oct 15;48(20):5837-41 [3262414.001]

[Cites] J Histochem Cytochem. 2004 Jan;52(1):19-28 [14688214.001]

[Cites] Mol Med. 2006 Jul-Aug;12(7-8):161-70 [17088948.001]

[Cites] Acta Neuropathol. 2004 Jul;108(1):43-8 [15088099.001]

[Cites] J Neurosci Res. 2005 Aug 1;81(3):447-55 [15959903.001]

[Cites] J Nucl Med. 2007 Jan;48(1):158-67 [17204713.001]

[Cites] Science. 2005 May 27;308(5726):1314-8 [15831717.001]

[Cites] Neurogenetics. 2004 Jun;5(2):95-108 [15042428.001]

[Cites] J Neurosci Res. 2005 Aug 1;81(3):327-41 [15948185.001]

[Cites] J Neurosci Res. 2006 May 15;83(7):1293-8 [16547968.001]

[Cites] Brain Res. 1990 Jun 4;518(1-2):199-208 [2167748.001]

[Cites] Ann Neurol. 1989 Dec;26(6):752-8 [2557794.001]

[Cites] Cancer Lett. 2000 Aug 11;156(2):125-32 [10880761.001]

[Cites] J Nucl Med. 1991 Aug;32(8):1608-10 [1651383.001]

[Cites] J Neurooncol. 2007 Jan;81(1):1-7 [16868661.001]

[Cites] Trends Neurosci. 2006 Feb;29(2):68-74 [16406093.001]

[Cites] Pharmacol Ther. 2006 Jun;110(3):503-24 [16337685.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4375-81 [11389063.001]

[Cites] J Neurochem. 2002 Nov;83(3):546-55 [12390516.001]

[Cites] Eur J Pharmacol. 1992 Sep 1;228(2-3):131-9 [1332878.001]

[Cites] J Recept Signal Transduct Res. 2003;23(2-3):225-38 [14626449.001]

[Cites] J Neuroinflammation. 2005 Oct 31;2:24 [16259628.001]

[Cites] J Neurocytol. 1997 Feb;26(2):77-82 [9181482.001]

[Cites] Trends Neurosci. 1996 Aug;19(8):312-8 [8843599.001]

[Cites] Pharmacol Rev. 1999 Dec;51(4):629-50 [10581326.001]

[Cites] Cytometry. 1996 May 1;24(1):39-48 [8723901.001]

[Cites] Cancer Res. 1995 Jun 15;55(12):2691-5 [7780986.001]

[Cites] Neuro Oncol. 2006 Jul;8(3):261-79 [16775224.001]

[Cites] IEEE Trans Med Imaging. 2003 Mar;22(3):289-301 [12760547.001]

[Cites] Life Sci. 2004 Jan 30;74(11):1387-95 [14706569.001]

[Cites] Ann Neurol. 1989 Oct;26(4):564-8 [2554790.001]

[Cites] Glia. 2005 Sep;51(4):279-85 [15818597.001]

[Cites] J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40 [8784228.001]

[Cites] Brain. 2000 Nov;123 ( Pt 11):2321-37 [11050032.001]

[Cites] Cancer. 1990 Jan 1;65(1):93-7 [2152852.001]

(PMID = 17520179.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Grant] United Kingdom / Medical Research Council / / MC/ U120085814

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Isoquinolines; 0 / RNA, Messenger; 0 / Radiopharmaceuticals; 0 / Receptors, GABA-A; YNF83VN1RL / PK 11195

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Twenty-three Glioblastoma Multiforme and two Anaplastic Astrocytoma were studied.

The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.

No grade 4 CTCAE (version 3.0) toxicities were observed.

ii) the regimen resulted in improvement of survival of RPA classes IV, V, VI; and iii) the use of FSRT boost may be studied with other chemotherapeutic agents to see if superior results can be attained.

[MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Brain Neoplasms / therapy. Glioma / therapy. Paclitaxel / pharmacokinetics. Radiosurgery / methods

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. TAXOL .

Hazardous Substances Data Bank. PHENYTOIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17535024.001).

[ISSN] 1533-0346

[Journal-full-title] Technology in cancer research & treatment

[ISO-abbreviation] Technol. Cancer Res. Treat.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 6158TKW0C5 / Phenytoin; P88XT4IS4D / Paclitaxel

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.

BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).

Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).

[MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.

Genetic Alliance. consumer health - Oligodendroglioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19197992.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of concurrent bevacizumab with brain irradiation has not been extensively studied.

METHODS AND MATERIALS: After prior treatment with standard radiation therapy patients with recurrent glioblastoma (GBM) and anaplastic gliomas (AG) received bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression.

Three patients discontinued treatment because of Grade 3 central nervous system intratumoral hemorrhage, wound dehiscence, and bowel perforation.

[MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma. Brain Neoplasms. Neoplasm Recurrence, Local. Radiosurgery

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Clin Oncol. 2004 Dec;27(6):646-8 [15577450.001]

[Cites] BMC Cancer. 2005;5:55 [15924621.001]

[Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]

[Cites] Neurosignals. 2005;14(5):207-21 [16301836.001]

[Cites] Lung Cancer. 2006 Jan;51(1):97-103 [16213059.001]

[Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]

[Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]

[Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]

[Cites] Acta Oncol. 2006;45(7):848-55 [16982549.001]

[Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]

[Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]

[Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]

[Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]

[Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]

[Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]

[Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]

[Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 [15001240.001]

[Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]

[Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]

[Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]

[Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]

[Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]

[Cites] Cancer Res. 1986 Feb;46(2):723-7 [3940638.001]

[Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]

[Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]

[Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]

[Cites] Radiother Oncol. 2007 Feb;82(2):185-90 [17257702.001]

[Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]

[Cites] Cancer Res. 2007 Jun 1;67(11):5076-82 [17545583.001]

[Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]

[Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]

[Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]

[Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]

[Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):484-90 [18234445.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]

[Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8 [17293237.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]

[Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):375-83 [9069310.001]

[Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]

(PMID = 19167838.001).

[ISSN] 1879-355X

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00595322

[Grant] United States / NCI NIH HHS / CA / P30 CA008748

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab

[Other-IDs] NLM/ NIHMS460357; NLM/ PMC3659401

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PFS-6 was achieved in five patients (33%), three with glioblastoma multiforme and two with anaplastic astrocytoma.

[MeSH-major] Antineoplastic Agents / therapeutic use. Benzothiazoles / therapeutic use. Brain Neoplasms / drug therapy. Epothilones / therapeutic use. Glioma / drug therapy

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuro Oncol. 2009 Apr;11(2):158-66 [18780814.001]

[Cites] Neurology. 2006 Feb 28;66(4):587-9 [16505319.001]

[Cites] Cancer J. 2008 Sep-Oct;14 (5):279-85 [18836331.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] J Clin Oncol. 1999 Jul;17(7):2069-80 [10561260.001]

[Cites] Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8 [17006870.001]

[Cites] Expert Opin Investig Drugs. 2008 Nov;17(11):1735-48 [18922109.001]

[Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]

[Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]

[Cites] Cancer Res. 2008 Jul 1;68(13):5301-8 [18593931.001]

[Cites] J Neurooncol. 2003 Nov;65(2):99-106 [14686728.001]

[Cites] Drugs. 2008;68(2):139-46 [18197722.001]

[Cites] Anticancer Drugs. 2008 Jul;19(6):613-20 [18525321.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]

(PMID = 19381446.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzothiazoles; 0 / Epothilones; 0 / sagopilone

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

QUESTION: What is the safety and efficacy of interstitial chemotherapy with carmustine-loaded polymers (Gliadel wafers: MGI Pharma, Bloomington, MN, U.S.A.) in the treatment of newly diagnosed or recurrent malignant glioma (that is, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligoastrocytoma, and anaplastic oligodendroglioma)?

PERSPECTIVES: Malignant glioma is the most common type of primary brain tumour in adults.

The most frequently reported adverse events were convulsions, confusion, brain edema, infection, hemiparesis, aphasia, and visual field defects.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]

[Cites] Surg Neurol. 2000 May;53(5):458-64 [10874145.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]

[Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]

[Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]

[Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]

[Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]

[Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]

[Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]

(PMID = 17938702.001).

[ISSN] 1198-0052

[Journal-full-title] Current oncology (Toronto, Ont.)

[ISO-abbreviation] Curr Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Other-IDs] NLM/ PMC2002480

[Keywords] NOTNLM ; Gliadel / carmustine / glioblastoma / interstitial chemotherapy / malignant glioma / systematic review

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.